The human genome: 2% codes for known proteins we’ve cataloged and targeted for drugs (left), while 98% was dismissed as non-functional “junk” (right). Enara’s Darkfox discovery proves cancer expresses druggable antigens from this dark genome—tumor-specific targets that normal cells don’t produce, entering clinical trials with ENA-101 in 2026.
